Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

GNPS - 10 mg/kg PheCA, SerCA dosing via PBFM

ABSTRACT: Data from 10 mg/kg MCBA dosing via peanut butter feeding method.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Mus Musculus (ncbitaxon:10090)

SUBMITTER: Douglas Guzior Robert Quinn

PROVIDER: MSV000093170 | GNPS | Fri Oct 20 20:10:00 BST 2023

REPOSITORIES: GNPS

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

10 mg/kg PheCA, SerCA dosing via PBFM

Project description:Data from 10 mg/kg MCBA dosing via peanut butter feeding method.

2023-10-20 | MSV000093170 | MassIVE

100 mg kg serocholate dosing via PBFM

Project description:Data from 100 mg/kg SerCA dosing via PBFM (peanut butter feeding method).

2023-10-20 | MSV000093169 | MassIVE

GNPS - 100 mg kg serocholate dosing via PBFM

Project description:Data from 100 mg/kg SerCA dosing via PBFM (peanut butter feeding method).

2023-10-20 | MSV000093169 | GNPS

80 mg/kg mixed MCBA dosing (10 mg/kg indiv.) via PBFM

Project description:Mixed MCBA PBFM dosing of wild-type C57BL/6Crl mice. 80 mg/kg total bile acid dose (10 mg/kg individual MCBA). MCBAs included in the dosing included AlaCA, AspCA, GluCA, LeuCA, PheCA, SerCA, ThrCA, and TyrCA.

2023-10-21 | MSV000093171 | MassIVE

GNPS - 80 mg/kg mixed MCBA dosing (10 mg/kg indiv.) via PBFM

2023-10-21 | MSV000093171 | GNPS

10 mg/kg MCBA dosing via PBFM - SerCA, Ser+CA, PheCA, Phe+CA, TCA, T+CA, Mock

Project description:C57BL/6Crl mice were fed 10 mg/kg BA or control for 13 days. Samples collected on day 14. Treatment groups included serocholate, serine + cholate, phenylalanocholate, phenylalanine + cholate, taurocholate, taurine + cholate, and a mock control. Fecal, F; Colon, CL; Cecum, CE; Duodenum, DD; Gallbladder, GB; Ileum, IL; Liver, L

2023-10-21 | MSV000093172 | MassIVE

Gene Expression during Panobinostat Dosing

Project description:A clinical study evaluating the dosing of an oral HDACi panobinostat in patient infected with HIV-1. Dosing was 20 mg orally, 3 times weekly, every other week for a total of 8 weeks. Gene expression was evaluated in whole PBMCs at baseline (Visit 2), after 3 doses (Visit 4), 4 weeks after dosing (Visit 12) and 6 months after dosing (Visit 13) using the Affymetrix HTA 2.0 gene expression chip

2018-01-30 | GSE109792 | GEO

ATAC-seq for LuCaP145.2 tumors treated with 50 mg/kg JQ1 or 10 mg/kg AZD5153 for 7 days

Project description:ATAC-seq for LuCaP145.2 tumors treated with 50 mg/kg JQ1 or 10 mg/kg AZD5153 for 7 days

| PRJNA1104154 | ENA

Effects of neonatal dosing of SERMs on CD1 mouse uterine gene expression at 3 months

Project description:Tamoxifen, a selective estrogen receptor modulator (SERM), is an effective treatment for breast cancers. In the CD-1 mouse model, neonatal oral dosing with tamoxifen leads to the development of adenomyosis. Both 4-hydroxyestradiol and tamoxifen can form DNA-reactive metabolites and may be involved in carcinogenesis of the uterus. After comparing the uterotrophic response of several SERMs the maximal uterotrophic doses of estradiol (100mg/kg) 4-hydroxyestradiol (385mg/kg) and tamoxifen (250mg/kg) were determined. Maximal uterotrophic doses were given orally to newborn CD-1 mice on days 1 â 4 after birth and gene and pathological changes examined in the uterus at 3 months after dosing. ERKOa knockout mice were dosed orally with tamoxifen (1mg/Kg) on days 1 â 4 after birth and uterine gene expression compared with CD-1 mice. Dosing groups: Estradiol (E2): 100mg/Kg 4-hydroxyestradiol (4OHE2): 385mg/Kg Tamoxifen : 250mg/Kg ERKO mice dosed with tamoxifen (1mg/Kg) 4 dosed animals and 4 controls for each treatment group. Uteri removed at 3 months after dosing and total RNA extracted. Controls were pooled. RNA labelling, hybridisation and analysis of fluorescence was carried out as described by Turton et al (2001). Cy3/Cy5 dye swap labelling was carried out on samples from each animal. Reference: Turton NJ et. al. (Oncogene (2001) 20, 1300-1306

2010-06-30 | E-GEOD-3625 | biostudies-arrayexpress

Effects of neonatal dosing of SERMs on CD1 mouse uterine gene expression at 3 months

2005-12-02 | GSE3625 | GEO